Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ p14ARF Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA116639
Description
p14ARF tends to run slightly higher than the theoretical MW of 14 kDa. Suggested positive control: BT549 cells or HeLa whole cell extract, antigen standard for CDKN2A (transient overexpression lysate).
The INK4a locus on chromosome 9p21 is frequently affected in human tumors. It encodes two structurally distinct tumor suppressor proteins, p16INK4a and the alternative reading frame protein, ARF (p14ARF in human and P19ARF in mouse). These two proteins interact with the upstream proteins: retinoblastoma protein and p53 tumor suppressors, respectively. Each of these proteins has a role in the senescence of primary cells, activates pathways for cell cycle control and tumor suppression. The p14ARF (or P19ARF in mouse) proteins can induce both G1 and G2 phase arrest in a manner that depends on functional p53. The mouse and human ARF proteins have different functions in tumor suppression; this distinction may contribute to the different levels of tumor proneness of these species.
Specifications
p14ARF | |
Polyclonal | |
Unconjugated | |
CDKN2A | |
Alternative reading frame; ARF; ARF-INK4a; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; CDKN2A; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; p14 p16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; P16INK4A; P16-INK4A; P19; P19 TP16; p19>ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF | |
Rabbit | |
Antigen Affinity Chromatography | |
RUO | |
1029, 12578 | |
-20°C or -80°C if preferred | |
Liquid |
Flow Cytometry, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot, Immunocytochemistry, Western Blot | |
1 mg/mL | |
PBS with 0.05% sodium azide | |
P42771, Q64364, Q8N726 | |
CDKN2A | |
A synthetic peptide made to a portion of human p14ARF (between residues 50-150). | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction